| **Statement of Deficiencies** | **(X1) Provider/Supplier/CLIA Identification Number** | **(X3) Date Survey Completed** |
|---|---|---|
| | 39D2051540 | 09/22/2026 |
| **Name of Provider or Supplier** | **Street Address, City, State** | |
| Forefront Dermatology, Sc | 2790 Mosside Blvd, Suite 720, Monroeville, PA | |

For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.

| (X4) ID Prefix Tag | Summary Statement of Deficiencies |
|---|---|
| **D5475** | CONTROL PROCEDURES<br>CFR(s): 493.1256(e)(3)(g)<br><br>(e)(3) Check fluorescent and immunohistochemical stains for positive and negative reactivity each time of use.<br><br>This STANDARD is not met as evidenced by:<br>Based on review of the laboratory's quality control (QC) staining records, immunohistochemical (IHC) stain policy, and interview with the Team Lead, the laboratory failed to check IHC stains for negative and positive staining reactivity each time of use for Mohs microscopic slide examinations performed for 17 of 17 months from 4/15/2025 to the day of the survey. Findings Include: 1. On the day of the survey, 9/22/2026 at 2:17 pm, review of the laboratory's MART 1 QC Assessment of Mohs Tissue Staining records revealed the laboratory failed to document negative and positive staining reactivity each time IHC stains (MART 1) were used for Mohs microscopic slide examinations performed for 17 of 17 months from 4/15/2025 to 9/22/2026. 2. The laboratory's IHC Direct Mart-1 Policy for Mohs surgery stated, "Positive and negative controls cut from patient debulk. There must be a positive and negative control slide each time the Mart-1 protocol is used." 3. Review of the laboratory's test logs revealed the laboratory performed 56 Mohs microscopic slide examinations using MART 1 stain from 4/15/2025 to 9/22/2026. 4. The Team Lead confirmed the findings above on 9/22/2026 at 3:00 pm. |